

January 20, 2020

Davies Scores Top Ranking in *Global Competition Review* 2020

For the 12th consecutive year, *Global Competition Review* has named Davies an “Elite” Canadian firm in its annual listing of the world’s top competition practices – the highest category awarded in the jurisdiction.

The guide commends our role in a “long list of global deals” over the past year, as well as our continued track record of success in competition litigation. A sampling of our recent notable work includes acting for Celgene Corp. in its proposed US\$74-billion purchase by Bristol-Myers Squibb Co.; acting for Monsanto on its €57-billion sale to Bayer, Pfizer on its proposed deal with GlaxoSmithKline related to their consumer healthcare businesses; and the Liquor Control Board of Ontario in successfully defending a multi-billion dollar class action alleging a price-fixing conspiracy.

Compiled independently, the GCR 100 provides a qualitative analysis of the law firms doing the most important competition and antitrust work around the world.